{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:33:30Z","timestamp":1791905610431,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"9983","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","thelancet.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/s0140-6736(14)60493-1","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T20:40:00Z","timestamp":1419280800000},"page":"2197-2208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":532,"title":["Multiple myeloma"],"prefix":"10.1016","volume":"385","clinical-trial-number":[{"clinical-trial-number":"nct01191060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01208766","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christoph","family":"R\u00f6llig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(14)60493-1_bib1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib3","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(14)60493-1_bib4","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(14)60493-1_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(14)60493-1_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib8","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(14)60493-1_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/S0140-6736(14)60493-1_bib11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2012.03.001","article-title":"What do I need to know about immunoglobulin light chain (AL) amyloidosis?","volume":"26","author":"Dispenzieri","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/S0140-6736(14)60493-1_bib13","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib17","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004023","article-title":"Early versus deferred treatment for early stage multiple myeloma","volume":"1","author":"He","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(14)60493-1_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.ackd.2012.06.001","article-title":"Current approach to diagnosis and management of acute renal failure in myeloma patients","volume":"19","author":"Leung","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/S0140-6736(14)60493-1_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1517\/14656566.2013.803068","article-title":"Current treatments for renal failure due to multiple myeloma","volume":"14","author":"Kastritis","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/S0140-6736(14)60493-1_bib22","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-11-0498","article-title":"Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment","volume":"18","author":"Chanan-Khan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(14)60493-1_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.1992.10.4.587","article-title":"Curability of solitary bone plasmacytoma","volume":"10","author":"Dimopoulos","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib24","first-page":"101","article-title":"Radiotherapy in the management of plasma cell tumors","volume":"14","author":"Hu","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/S0140-6736(14)60493-1_bib25","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1002\/cncr.26031","article-title":"Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy","volume":"117","author":"Reed","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(14)60493-1_bib26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib27","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60493-1_bib28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(14)60493-1_bib30","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib32","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/S0140-6736(14)60493-1_bib34","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m(2) versus melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib35","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib36","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(14)60493-1_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000318880","article-title":"Treatment of patients with multiple myeloma: an overview of systematic reviews","volume":"125","author":"Kumar","year":"2011","journal-title":"Acta Haematol"},{"issue":"suppl","key":"10.1016\/S0140-6736(14)60493-1_bib40","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/jco.2013.31.15_suppl.8509","article-title":"Melphalan\/prednisone\/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients","volume":"31","author":"Boccadoro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib41","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(14)60493-1_bib42","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2011-0391","article-title":"European perspective on multiple myeloma treatment strategies: update following recent congresses","volume":"17","author":"Ludwig","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/S0140-6736(14)60493-1_bib44","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib47","first-page":"2367","article-title":"Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma","volume":"112","author":"Yeh","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/S0140-6736(14)60493-1_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.21904","article-title":"Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib49","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib51","first-page":"2","article-title":"Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT)","volume":"122","author":"Facon","year":"2013","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/S0140-6736(14)60493-1_bib52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib54","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(14)60493-1_bib56","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib57","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib58","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib59","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(14)60493-1_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/S0140-6736(14)60493-1_bib61","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib64","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib65","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib66","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-10-1925","article-title":"Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival","volume":"17","author":"Palumbo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(14)60493-1_bib67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(14)60493-1_bib68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-009-0726-6","article-title":"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib\/dexamethasone for remission induction in patients with newly diagnosed myeloma","volume":"88","author":"Kropff","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib69","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib70","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib72","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib73","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib74","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.22237","article-title":"Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib77","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib78","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib79","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib81","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib82","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib83","first-page":"1855","article-title":"Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): a meta-analysis","volume":"118","author":"Nooka","year":"2011","journal-title":"ASH Annu Meet Abstr"},{"issue":"suppl 2","key":"10.1016\/S0140-6736(14)60493-1_bib84","first-page":"884","article-title":"Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials","volume":"96","author":"Hahn-Ast","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(14)60493-1_bib85","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib87","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60493-1_bib88","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib91","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60493-1_bib92","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib93","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib94","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib95","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib97","first-page":"944","article-title":"Analysis of second-Line lenalidomide following initial relapse in the MM-015 trial","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/S0140-6736(14)60493-1_bib98","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(14)60493-1_bib99","first-page":"3086","article-title":"Autologous Re-transplantation for patients with relapsed multiple myeloma: a single center experience with 200 patients","volume":"120","author":"Neben","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/S0140-6736(14)60493-1_bib100","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib101","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.1999.17.7.2173","article-title":"High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial","volume":"17","author":"Vesole","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib102","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(14)60493-1_bib104","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib105","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/S0140-6736(14)60493-1_bib106","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1445-5994.2008.01824.x","article-title":"Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment","volume":"39","author":"Dickinson","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/S0140-6736(14)60493-1_bib107","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(14)60493-1_bib108","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(14)60493-1_bib109","first-page":"3972","article-title":"Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents","volume":"120","author":"Kumar","year":"2012","journal-title":"ASH Annu Meet Abstr"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673614604931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673614604931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T01:11:23Z","timestamp":1598577083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673614604931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":107,"journal-issue":{"issue":"9983","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0140673614604931"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(14)60493-1","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}